Clinical Trials Logo

Chronic Pulmonary Aspergillosis clinical trials

View clinical trials related to Chronic Pulmonary Aspergillosis.

Filter by:

NCT ID: NCT03656081 Recruiting - Clinical trials for Chronic Pulmonary Aspergillosis

Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole

Start date: December 19, 2018
Phase: Phase 3
Study type: Interventional

This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by itraconazole alone, in non - or mildly - immunocompromised patients affected by Chronic Pulmonary Aspergillosis (single aspergilloma excluded). • Control arm: Itraconazole 200 mg x 2/day associated with inactive nebulised treatment twice a week during 24 weeks. • Experimental arm: Itraconazole 200 mg x 2/day associated with nebulised LAmB, at 25 mg twice a week during 24 weeks. Follow up duration for the patients will be 24 months (12 months minimum) after discontinuation of the treatment being studied.

NCT ID: NCT03059992 Completed - Clinical trials for Invasive Candidiasis

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

FURI
Start date: April 1, 2017
Phase: Phase 3
Study type: Interventional

This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.

NCT ID: NCT03027089 Recruiting - Clinical trials for Chronic Pulmonary Aspergillosis

Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study

Start date: January 2017
Phase: N/A
Study type: Observational

Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)